에이치엘비는 끊임없는 열정과 노력으로 다양한 사업분야에서
미래의 변화를 주도하고 있습니다.
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular c
Rationale: Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as standard treatment for advanced HCC, its treatment efficacy is limited. Effective treatments for patients with advanced HCC that progresses on or after sorafenib treatment or patients who are intolerant of sorafenib remain an unmet medical need.
Patient concerns: We report an advanced HCC patient with many lung metastases who failed sorafenib treatment.
Diagnoses: Sorafenib refractory HCC patient with a large number of lung metastases.
Interventions: The apatinib alone was used as second line therapy.
Outcomes: The patient achieved partial response (PR) soon after the treatment, which was maintained for approximately 1 year.
During the entire process, the lung metastases continued to diminish. Finally, only a few lesions remained
Lessons: Apatinib alone may be a good second-line therapy for advanced HCC patients who are refractory to sorafenib. However,
further investigation in future prospective clinical studies is warranted.
Abbreviations: AFP = alpha fetoprotein, CT = computed tomography, HCC = hepatocellular carcinoma, PD = progression
disease, PFS = progression-free survival, PR = partial response, TACE = transcatheter arterial chemoembolization, VEGF = vascular
endothelial growth factor.